Reduced Dose Anthracycline Pre Breast Cancer Surgery Has No Effect On Outcome

Canadian researchers have discovered that there is a low risk of adverse effect from reducing pre-op chemo by up to 25%, according to findings published in the online journal ecancermedicalscience.


The study, undertaken at the British Columbia Cancer Agency, Vancouver, found that women with early stage breast cancer treated with up to 4 courses of standard adjuvant anthracycline showed no relationship between dose intensity and clinical outcome, despite nearly a decade of follow-up.


Between 1990 and 1995, 484 patients were assessed in 4 groups: 1- all cycles delivered at full dose and on time; 2- one single dose reduction or dose delay; 3- >1 dose reduction or dose delay; and 4-